Quick Answer
VACCINEX, INC. reported Operating Income Loss of -$18.74 million for the year ending 2024.
- VACCINEX, INC. showed an increase of +18.1% in Operating Income Loss from 2023 to 2024.
- This data is from VACCINEX, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$4.67 million | Q3 2017: -$5.33 million | Q1 2018: -$5.71 million | Q2 2018: -$6.56 million | Q3 2018: -$6.45 million | Q1 2019: -$9.14 million | Q2 2019: -$8.86 million | Q3 2019: -$7.68 million | Q1 2020: -$7.16 million | Q2 2020: -$6.50 million | Q3 2020: -$8.58 million | Q1 2021: -$6.24 million | Q2 2021: -$5.67 million | Q3 2021: -$5.06 million | Q1 2022: -$4.59 million | Q2 2022: -$5.40 million | Q3 2022: -$4.79 million | Q1 2023: -$4.99 million | Q2 2023: -$7.08 million | Q3 2023: -$5.83 million | Q1 2024: -$5.07 million | Q2 2024: -$5.72 million | Q3 2024: -$4.55 million.
- Over the full 8 years of available data (2017 to 2024), VACCINEX, INC.'s Operating Income Loss has grown by 11.2%.
- Historical annual values: Fiscal year 2024: -$18.74 million | Fiscal year 2023: -$22.89 million | Fiscal year 2022: -$19.91 million | Fiscal year 2021: -$22.49 million | Fiscal year 2020: -$28.33 million | Fiscal year 2019: -$32.02 million | Fiscal year 2018: -$27.28 million | Fiscal year 2017: -$21.10 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: